TruGenomix Health will launch a revolution in treatment for post-traumatic stress disorder (PTSD), offering better identification of the condition and targeted, individualized treatment options. TruGenomix is the brainchild of two veterans, Yusuf Henriques and Charles Cathlin. The two met in 2006 as scientific reviewers in the FDA's Center for Devices and Radiological Health and bonded over a shared desire to improve medical treatment for veterans and entrepreneurs' frustration at the pace of innovation.